BACKGROUND Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L-asparaginase (L-ASP) has not been studied. HYPOTHESIS/OBJECTIVES To evaluate the safety and efficacy of L-ASP given concurrently with RAB in dogs with relapsed multicentric lymphoma. ANIMALS Fifty-two dogs with relapse of lymphoma after treatment with at least 1 doxorubicin-based chemotherapy protocol. METHODS Open-label, multicenter, prospective single-arm clinical trial. Dogs were treated with RAB at 1.0 mg/kg IV every 21 days for up to a total of 5 doses. L-asparaginase was administered at 400 IU/kg SQ concurrently with the first 2 treatments of RAB. RESULTS The overall response rate (ORR) for all dogs was 67%, with 19 dogs (41%) achieving a complete response (CR). The median progression-free survival time (MPFS) was 63 days (range 5-428 days). Dogs experiencing a CR as their best response had an MPFS of 144 days (range 44-428 days). Adverse events were similar to previous studies evaluating single agent RAB. Failure to achieve a CR and having previously received L-ASP were negative prognostic factors on multivariate analysis. CONCLUSIONS AND CLINICAL IMPORTANCE Concurrent RAB/L-ASP appears to be both efficacious and safe for treating relapsed multicentric lymphoma in dogs. Adverse events were most often mild and no unexpected toxicoses were observed.

中文翻译：

---

同时使用拉巴沙汀和L-天冬酰胺酶治疗狗复发或难治性多中心淋巴瘤。

背景技术拉巴沙丁（RAB）是一种有条件地被许可用于治疗犬淋巴瘤的新型抗肿瘤药，对幼稚和先前治疗的犬均有效。尚未研究将其与L-天冬酰胺酶（L-ASP）结合使用。假设/目的为了评估多发性淋巴瘤复发狗中与RAB同时使用的L-ASP的安全性和有效性。动物用至少一种基于阿霉素的化疗方案治疗后，有52只狗患有淋巴瘤复发。方法开放标签，多中心，前瞻性单臂临床试验。每21天以1.0 mg / kg IV的RAB对犬进行治疗，总共5剂。L-天冬酰胺酶与RAB的前两种治疗同时以400 IU / kg SQ施用。结果所有犬的总缓解率（ORR）为67％，有19只狗（41％）达到了完全反应（CR）。中位无进展生存时间（MPFS）为63天（范围5-428天）。经历CR最佳反应的狗的MPFS为144天（44-428天）。不良事件与先前评估单药RAB的研究相似。未能达到CR且先前曾接受过L-ASP是多因素分析中的阴性预后因素。结论和临床意义并发RAB / L-ASP似乎对治疗狗复发性多中心淋巴瘤既有效又安全。不良事件最常见的是轻度的，没有观察到意外的毒性。不良事件与先前评估单药RAB的研究相似。未能达到CR且先前曾接受过L-ASP是多因素分析中的阴性预后因素。结论和临床意义并发RAB / L-ASP似乎对治疗狗复发性多中心淋巴瘤既有效又安全。不良事件最常见的是轻度的，没有观察到意外的毒性。不良事件与先前评估单药RAB的研究相似。未能达到CR且先前接受过L-ASP是多因素分析中的不良预后因素。结论和临床意义并发RAB / L-ASP似乎对治疗狗的复发性多中心淋巴瘤既有效又安全。不良事件最常见的是轻度的，没有观察到意外的毒性。